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Abstract: 
Objectives:  
It is well established that UK Asians typically have lower vitamin D levels than Caucasians. It is also 
known that vitamin D binding protein (DBP) is lower in some races than Caucasians. To investigate 
how ethnicity, skin colour and genetic variation affect the response to vitamin D (150,000 IU) 
administered to young Asian and Caucasian men. 
Design:  
Prospective, single centre clinical trial 
Participants: 
Sixty young men (18-25yr) of Asian (n=30) and Caucasian (n =30) origin 
Measurements:  
We measured serum calcium, phosphate, magnesium, alkaline phosphatase, albumin, parathyroid 
hormone; total 25 hydroxyvitamin D (25OHD); calculated and directly measured free 25OHD; DBP at 
baseline and 4 weeks; DBP genotype, skin colour (Fitzpatrick scale), dietary vitamin D and calcium 
intake at baseline; and urine calcium:creatinine ratio at baseline, 1 and 4 weeks. 
Results 
At baseline, Asians had lower serum total 25OHD (26.4 [13.7] vs 34.1 [12.3] nmol/l p=0.0272) and 
DBP (6.7 [3.4] vs 9.6 [4.4] nmol/l; p=0.0065) but similar free 25OHD (16.7 [10.4] vs 17.8 [7.5] pmol/l 
p=0.6530).  After dosing, total 25OHD rose similarly in each group (≈56 nmol/l), but measured free 
25OHD rose more in Asians (18.1 [9.4] vs 12.2 [13.3] pmol/L p=0.0464). Lower DBP at baseline, 
possibly reflecting genotype differences, was associated with a greater change in measured free 
25OHD in Caucasians, but not in Asians.  
Conclusions 
Asian compared with Caucasian males had a larger increment in measured free 25OHD following 
150,000 units vitamin D3, possibly reflecting differences in DBP affinity for 25OHD. Ethnicity should 
be considered when devising guidelines for the treatment of vitamin D deficiency. 
Key words: 
Bio-available 25 hydroxy vitamin D, Ethnicity, Serum Measured Free 25 hydroxy vitamin D, Vitamin D 
binding protein, Vitamin D binding protein genotype, Vitamin D3. 
 
 
Page 3 of 23 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 4 
MAIN TEXT FILE 
Introduction:  
Vitamin D deficiency is a term widely used but rarely defined in terms of functional outcomes. 
Based on synthesised evidence, thresholds for low dose supplementation or higher dose 
treatment have been suggested. The Scientific Advisory Committee on Nutrition Department 
(SACN) recommends a threshold of 25 nmol/L for serum 25OHD for all individuals at any time of 
the year to protect the musculoskeletal health.[1] The Institute of Medicine defines the threshold 
for vitamin D deficiency  as  ≤30 nmol/L.[2] The Endocrine Society defines the threshold for 
vitamin D deficiency as <50nmol/L, which would likely include more than half the population of 
the UK during winter months.[3]  
 
What remains unclear is the extent to which “one size fits all” in providing vitamin D 
supplementation or treatment. In the UK, vitamin D deficiency is widely reported, more so in 
those with darker skin including those of African or Asian descent. The effect of ethnicity, 
independently of other factors, has not previously been considered when devising strategies and 
recommendations for either low dose supplementation or higher dose treatment. 
 
Vitamin D status is currently assessed by measuring circulating 25-hydroxyvitamin D (25OHD), 
which exists either free in the circulation (<1%), or bound to albumin or the vitamin D-binding 
protein (DBP). The terms “free” vitamin D and “bioavailable” vitamin D refer respectively to 
unbound 25OHD, or unbound plus 25OHD bound to albumin. The extent to which the total 
measurement adequately reflects either free or bioavailable serum 25OHD and whether any 
relationship between “total” and “free” varies following supplementation, or with other factors 
such as ethnicity, is unclear. Reports of higher free and bioavailable serum 25OHD for the same 
total serum 25OHD in African Americans have been challenged because of concerns regarding 
DBP measurement accuracy [12,13,15,16,17].  
 
In light of this, we sought to investigate whether there were differences between serum total and 
directly measured free 25OHD concentrations between Asians and white Caucasians and the 
changes in these parameters following administration of a single dose of 150,000 IU of vitamin 
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D3. In addition, we aimed to determine the effect of covariates including DBP concentration and 
genotype, concurrent diet and skin colour on both the free and total 25OHD responses, and the 
extent of parathyroid hormone (PTH) suppression following dosing.  
 
Materials and methods: 
Study design: This was an exploratory study to determine the size of the effect on serum free and 
total 25OHD of a 150,000 unit dose of vitamin D3, given to young adults from different ethnic 
groups (Figure 1).  
Study participants: We recruited a cohort of sixty apparently healthy young adult men from two 
ethnic groups - White Caucasian (n=30) or South/East Asian (n=30) origin. Eligibility criteria included 
men aged between 18 and 25 years who were free from any condition affecting bone health, general 
nutrition, growth and glucose metabolism. Subjects with any chronic illness involving the liver and 
kidney, causing malabsorption, who used steroids, anticonvulsants, or vitamin D treatment as well 
supplementation or any medication that might affect calcium and vitamin D metabolism, were 
excluded. Recruitment took place within the University of Sheffield using a mixture of email, 
posters/leaflets and pre-lecture 2-minute talks. Subjects were students of the University of Sheffield, 
mostly medical and dental students. None of the study participants travelled to destinations where 
cutaneous vitamin D synthesis could have taken place during the study period. Whilst it was 
anticipated that gender should not impact on the outcome, the administration of a large dose of 
vitamin D3 might have had unexpected effects on an early stage pregnancy, thus we excluded young 
women.  
 
Demography and auxology: At baseline, height (without shoes to next succeeding 1mm by wall-
mounted stadiometer [Holtain, Crymych]), weight (wearing vest and pants to nearest 0.1 kg by 
Marsden portable weighing scales, body mass index [BMI (kg/m
2
), and waist:hip circumference ratio 
(paper tape measure) were recorded in all subjects. 
 
Dietary calcium and vitamin D intake: A validated 101-item food frequency questionnaire (DIET-Q) 
was used to ascertain the dietary intake of calcium and vitamin D at baseline. Mean daily calcium 
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(grams/day) and vitamin D (IU/day) intake were analysed using Q Builder (V4.0) nutritional software 
(Tinuviel software, Llanfechell, Anglesey UK). 
 
Skin type, season and sun exposure: Skin type was assessed using a 6-point Fitzpatrick scale in all 
subjects at baseline [4]. Fitzpatrick 1 skin type is fair and freckled; type 6 is very dark/black.  The 
study was conducted in the UK during January and February to avoid sun exposure.  
 
Samples: 
Baseline: Fasting blood samples were collected for serum total 25OHD, free 25OHD, calcium, 
phosphate, magnesium, albumin, alkaline phosphatase, PTH, DBP and DBP genotype.  
Four weeks: All blood investigations (except DBP genotype) were repeated.  
Urinary calcium:creatinine ratio: A fasting second void urine sample for calcium:creatinine ratio 
was collected at baseline, 1 and 4 weeks after vitamin D3 administration. 
 
Vitamin D3 dosing:  
A single dose of 150,000 IU of Vitamin D3 [6 mls of Invita D3 (Consiliant) 25,000 IU/ml oral 
solution] was administered under direct supervision. We chose this dose based on the work done 
by Oliveri B et al where the authors demonstrated the safety of a single dose of 150,000 IU of 
vitamin D to maintain appropriate levels of 25OHD without causing hypercalcaemia or 
hypercalciuria [5].
 
 
Laboratory methods: 
Serum total 25OHD: Serum total 25OHD levels were determined using an UPLC/Mass Spectrometer 
Semi-automated hexane extraction in the Acquity Ultra Performance LC/Quattro MS (Waters) 
analyser. Lower limit of detection for 25OHD2 was 6 nmol/L and for 25OHD3 3.5 nmol/L. The 
interassay coefficient of variation (CV) for 25OHD2 and 25OHD3 were 5.7% and 5.4% respectively. 
Serum free 25OHD: Free 25OHD levels were measured using an ELISA from Future Diagnostics 
Solutions. The interassay CV was 4.8%.  
Serum Vitamin D binding Protein: DBP levels were measured using an ELISA from Genways Biotech 
Inc. The interassay CV was 5.8%. 
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 7 
Serum calcium, phosphate, albumin, and alkaline phosphatase; urine calcium, creatinine: 
Measured using Micro Slide Technology Colorimetric/Rate by Reflectance Spectrophotometry in the 
Vitros 5, 1 FS System (Ortho Clinical Diagnostics) analyser. The interassay CVs were: calcium (1.4%), 
phosphate (1.6%), albumin (2.9%), alkaline phosphatase (2.4%), urine calcium (1.7%) and urine 
creatinine (4.4%). 
Intact Parathyroid hormone (PTH): PTH was measured using Immunoassay (Chemiluminescent 
Microparticle Immunoassay) in the Architect i 1000 System (Abbot) [PTH analytical sensitivity ≤1 
ng/L]. 
DBP genotyping: A pyrosequencing assay was developed in house, using PSQ assay design 
software version 1.0.6 (Qiagen), to detect two single-nucleotide polymorphisms (SNPs), rs4588 
and rs7041 in the DBP gene, that give rise to 3 common variants of DBP (i) Gc1f (ii) Gc1s and (iii) 
Gc2.  All subjects were genotyped for 6 different haplotypes - Gc1f-1f, Gc1f -1s, Gc1f-2, Gc1s-1s, 
Gc1s-2, and Gc2-2, ranked here in order of 25OHD binding affinity, highest to lowest. 
PCR and sequencing primers were as follows:   
F: 5' -ATCTGAAATGGCTATTATTTTG-3',  
R: 5' Btn -ACAGTAAAGAGGAGGTGAGTT-3',  
Seq: 5' -AAAAGCTAAATTGCCTG-3'. 
To ensure distinct pyrosequencing signals, (~10 ng) of human genomic DNA was amplified by 47× 
PCR cycles using  OneTaq® 2X Master Mix with Standard Buffer (NEB). For each genotype 
determination, single-stranded DNA was purified from 5 μl of PCR products using PyroMark Q96 
Vacuum Prep Workstation (Qiagen). PCR products were denatured to single-stranded DNA 
(ssDNA) and annealed with sequencing primers. Pyrosequencing was then performed on a 
PyroMark Q96 MD Instrument according to manufacturer's instructions (Qiagen). Nucleotide 
dispensation order was as follows: DBP rs4588+rs7041 CATGTCACACACTG. SNP analysis was 
carried out using the SNP analysis software provided (Qiagen). 
 
Calculated free and bio-available 25OHD: Free and bioavailable 25OHD levels based on fixed affinity 
constant for the DBP genotype (Gc1f-1f) was calculated using the mathematical model described by 
Chun et al [6].  
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Sample size: 
This was an exploratory study to determine effect size and variance; hence no formal calculation 
of sample size was undertaken.  We sought advice from the Yorkshire and Humber Research 
Design Service who suggested that a sample size of 30 per group was sufficient to undertake 
exploratory work of this nature.  
 
Statistical methods: 
Continuously distributed data was summarized by the median (25
th
/75
th
 centiles); categorical data 
by n(%). Missing values are tabulated but not considered otherwise in our analysis. 
Normality checks were carried out; data were generally normally or near-Normally distributed, 
hence parametric tests were used to assess differences between groups. 
To compare the groups prior to dosing, 2 sample t-tests of baseline characteristics were 
performed and are reported in Table 1. 
 The main question of interest was whether ethnicity impacted on change in total and free 25OHD 
following dosing. Two sample t tests were carried out to compare the changes in total and free 
25OHD between the groups. Analysis of variance was also used to determine any other statistical 
differences between the groups and adjust for covariates. Generalized linear models were used to 
determine statistical differences between response variables that had error distribution models 
other than normal, and to assess the interactive effect of ethnicity and DBP on change in free 
25OHD.  
Fisher’s exact test was used to compare the categorical data.  Graphical presentation was made 
by Box and Whisker plot. P values were used sparingly with an arbitrary threshold of 0.05(two 
tailed). 
We performed all our analyses using Statistical Package for the Social Sciences version 22 (SPSS by 
IBM), Data Desk
TM
 v6.2.1, and Stata v14 [7]. For method comparison between directly measured 
serum free 25OHD and calculated free 25OHD, we used Medcalc for Windows, version 8.0 
(Medcalc Software, Mariekerke, Belgium) to perform Bland-Altman analysis[8] and Passing Bablok 
regression[9].  
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Results: 
Baseline clinical characteristics 
The baseline clinical characteristics of the study subjects are shown in Table 1. The white 
Caucasian and Asian men did not differ with respect to age, weight, height, BMI and waist to hip 
ratio. The mean (SD) Calcium intake (grams/day) was adequate and equal between the Asians 
[1031.23(382.6)] and white Caucasians [1065.87(266.88)]. The median (range) vitamin D intake 
(IU/day) in comparison with the UK recommended daily intake was low and similar between the 
groups, 140(74,276) and 120(20,524) in Asians and white Caucasians respectively. White 
Caucasians had a Fitzpatrick skin type of 1-3 and Asians 3-5. White Caucasians predominantly had 
Gc1s-2 haplotype and did not have Gc1f-1f and Gc1f-2. South Asians predominantly had Gc1s-1s 
haplotype and East Asians Gc1f-1f haplotype. Gc2-2 and Gc1s-2 were not found in East Asians 
(table 2). Table 2 shows the relationship between haplotype frequency and ethnicity. There was a 
significant association between the two (p=0.052, fisher’s exact test). There were more Asians 
with Gc1f-1f haplotype than expected [5 vs 2.5]. Similarly, more Caucasians with Gc2-1s 
haplotype than expected [11 vs.8.5].  
Table 2 shows the differences in baseline total 25OHD status between the different haplotypes 
and ethnicity. However, the numbers were too small for statistical comparison. 
 
Influence of ethnicity on measured parameters at baseline and following intervention 
Twenty-nine participants out of the 60 recruited had a serum total 25OHD level of < 30mnmol/L 
at baseline, of which 60% (18/30) were Asian and 36% (11/30) were white Caucasian (Table1). 
Asians had significantly lower serum total 25OHD and DBP levels, but similar measured and 
calculated free 25OHD levels compared to white Caucasians at baseline (Table 3). At four weeks 
the changes in serum total 25OHD, DBP, and calculated free 25OHD levels were similar between 
Asians and white Caucasians; however the increase in directly measured serum free 25OHD level 
was significantly greater in Asians 18.1(9.4) vs 12.2 (13.3) pmol/L in Caucasians (p=0.0464) (Table 
3) (Figure(s) 2a, 2b and 2c).  Although the observed significance was marginal, we considered it to 
be acceptable for a preliminary study. 
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There was a significant interaction (p=<0.01) between ethnicity and mean DBP in relation to 
change in free 25OHD following dosing. In Caucasians, a lower mean DBP was associated with a 
larger in increase in measured free 25OHD; this was not true for Asians, in whom the relationship 
of free 25OHD with mean DBP was positive, i.e as mean DBP increased, the change in free 25OHD 
also increased (Figure 2d). 
We found no clear effect of DBP haplotype within ethnic group on change in either total or free 
25OHD, either alone or in combination with other factors.  
Baseline PTH concentration was higher in Asians than in white Caucasians (p=0.0019) (Table 3). 
Following intervention, no significant changes in PTH levels were noted in either of the groups 
(Table 3).  No increase in urine calcium: creatinine ratio was noted at either 1 or 4 weeks post 
intervention. 
 
Method comparison between directly measured and calculated serum free 25OHD 
concentration using fixed affinity constant for the DBP genotype (Gc1f-1f) 
Bland-Altman plot at baseline shows clear evidence of bias and one outlying observation (Figure 
3a).  Passing Bablok plot at baseline shows small and non significant systematic bias (intercept = 
0.54, 95% CI -3.54, 3.05 pmol/L).  There is a significant proportional bias (slope = 0.43, 95% CI 
0.24, 0.71 pmol/L) (Figure 3c). 
Bland-Altman plot post supplementation shows no evidence of bias (Figure 3b). 
Passing Bablok plot post supplementation shows a large negative systematic bias (-13.29 pmol/L). 
This is not statistically significant (95% CI -33.82, 2.99 pmol/L). There is no significant proportional 
bias (slope =1.04, 95% CI 0.54, 1.70 pmol/L) (figure 3d).  
 
Relationship of PTH with total and free 25OHD 
There was a statistically significant negative correlation between PTH and total 25OHD at baseline 
(r=-0.442; p=0.0006) and post intervention (r=-0.452; p=0.0004). However, the relationship of PTH 
at baseline with measured free 25OHD did not reach significance at baseline (r=-0.245; p=0.0634) 
or following intervention (r=-0.061; p=0.6446). 
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Relationship of skin type with total and free 25OHD  
There was no statistically significant difference between skin types and baseline total 25OHD 
concentrations by one-way ANOVA (F (4,54)=2.08, p=0.0956). Post-dosing total 25OHD also did 
not differ between skin types. 
 
Relationship of DBP genotypes on total and free 25OHD 
There were no significant differences by DBP genotype for baseline total 25OHD (F ratio =1.0075, 
p=0.4225) or serum free 25OHD (F ratio =0.4838, p=0.7868). Following intervention, subjects with 
Gc1f-1s haplotype (high affinity for 25OHD) showed the greatest increment in serum total 25OHD 
(increment 60.65 (17.3) nmol/L; baseline 32.9 (14.0) nmol/L). Subjects with the lowest affinity 
haplotype Gc2-2 had the smallest increment in serum total 25OHD (increment 48.9 (6.9) nmol/L, 
baseline 18.4 (3.6) nmol/L). The increment in serum direct free 25OHD levels was greatest in 
subjects with the Gc2-1s (16.6 (10.2) pmol/L; low affinity haplotype), and lowest in subjects with 
Gc1f-1f (10.1 (11.9) pmol/L highest affinity haplotype). None of these differences reached 
statistical significance, however.  
 
Relationship of dietary calcium and vitamin D intake with PTH, DBP, total and free 25OHD 
There was no relationship of dietary calcium intake at baseline with baseline PTH, DBP, total or 
free 25OHD, or change in any of those parameters, either for the whole group or by ethnicity. 
 
Discussion:  
We found that serum total 25OHD was low in young men of White Caucasian and Asian ethnic 
origin during winter in Sheffield and increased similarly in both groups following administration of 
150,000 units of vitamin D3, but that measured free 25OHD increased more in those of Asian 
origin. We found a relationship between both baseline and mean DBP concentration and 
incremental change in measured free 25OHD according to ethnicity. As mean DBP rose, the 
incremental increase in free 25OHD reduced in Caucasians, and increased in Asians. This suggests 
that the binding affinity of DBP may vary with ethnic origin.   
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There is a biochemical basis for the differences in affinity of the different DBPs for vitamin D 
metabolites. Polymorphisms in the Gc gene (codominant alleles) give rise to three major 
electrophoretic variants of Gc (Gc1f, Gc1s, and Gc2), which differ by amino acid substitutions as 
well as glycosylation[9].  The amino acid sequence of the three isoforms 1f, 1s and 2 differ at 
positions 152, 311, 416 and 420[11].  The position 416 difference is functionally important as this 
site contains a branched trisaccharide that in turn is linked to sialic acid (1f), mannose (1s) or no 
sugar residue (2). Such post-translational modifications are likely to affect the properties of the 
isoforms. Indeed, the relative affinity constants differ, so that if 1f is assigned a value of 1, then 
the values for 1s and 2 are 0.536 and 0.321, respectively [12,6].  
 
Calculated estimates of free 25OHD were found to be significantly different from direct 
measurements, and showed a systematic bias. According to the free hormone hypothesis
 
[13], the 
biological action of 25OHD is exerted by its freely-available form (<1% of the total), not by the 
total circulating amount which comprises DBP-bound (85-90%) and albumin-bound (10-15%) 
forms plus free. There is support also for the concept of bioavailable 25OHD[14], comprising the 
albumin-bound and free fractions, suggesting that measurement of free or bio-available 25OHD 
concentration may provide a more meaningful marker of vitamin D function than total [15].   
The movement of DBP-bound 25OHD to bioavailable or free forms likely depends in part on the 
concentration of DBP and its binding affinity for 25OHD. Both ar  known to vary significantly both 
by and within ethnic groups. A recent report by Yao et al has also demonstrated significantly 
lower levels of DBP (p <0.001) measured using a monoclonal assay (165.3+/-90.4 ug//ml) in 
comparison with the polyclonal assay (418.7+/_99.0 ug/ml) in a Chinese population [16]. Powe et 
al in their cross sectional study reported that black Americans have lower total 25OHD and DBP 
resulting in similar concentrations of calculated bio-available 25OHD compared to white 
counterparts [14].
 
Bouillon et al showed similar results in Black Gambians compared to White 
Caucasians using the same DBP assay. In contrast, when they measured DBP using a polyclonal 
assay (as used here), in the same cohort, they did not find any difference between the groups 
[17].
 
Similarly, Aloia et al. reported identical concentrations of DBP between US blacks and whites, 
using a polyclonal assay [18]. Recently, Nielson et al.
 
compared the DBP assays used in the MrOS
 
[19] and MRC cohorts [20]
 
and characterised the molecular forms of DBP [21].
 
The authors 
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 13
reported that the difference in DBP levels between the Africans and Whites identified using a 
monoclonal assay disappeared when measured using polyclonal or proteomic methods [21]. This 
contrasts with our results; we found a significant difference in DBP levels between the Asians and 
White Caucasians using the polyclonal assay. Lower DBP levels have previously been documented 
in carriers of two Gc2 alleles [22-24].  We found no clear effect of genotype either at baseline or 
following intervention on serum DBP, irrespective of ethnicity. Since our population size is small 
the results in relation to DBP and genotype should be considered preliminary and thus need 
confirming in a larger population.   
 
We found directly measured serum free 25OHD at baseline in Asians and Caucasians to be very 
similar despite lower total 25OHD in Asians. We hypothesized originally that the lower DBP 
concentrations found in the Asians in our cohort were likely to be the reason for their comparable 
levels of free 25OHD. Following intervention with vitamin D3, no change in DBP levels were 
observed in either Asians or White Caucasians when compared to baseline, indicating that the 
serum DBP concentration is not altered by single dose supplementation. Our findings agree with 
those of with Sollid, where no effect of vitamin D3 on serum DBP concentration was shown in an 
interventional trial (20,000 IU D3 weekly for a year) in Caucasians [24]. 
 
We found a higher increment in measured free 25OHD concentration in Asians following vitamin 
D3 supplementation, despite a similar increment in total 25OHD concentration and no significant 
change in DBP concentration. In addition, the incremental increase in Caucasians’ serum free 
25OHD was inversely related to both baseline and mean DBP, whereas in Asians it was not. This 
implies that DBP affinity for vitamin D and its metabolites may be a key factor in the response of 
Asians to vitamin D treatment. The lack of a clear relationship with DBP genotype could imply that 
additional factors may be at play, or may be due to the small sample size. 
 
Alzaman et al. compared the differences in total and free 25OHD levels between Black and White 
Americans following daily D3 supplementation (2000 IU or 4000 IU) or placebo for a total of 
sixteen weeks in nearly 200 diabetic subjects. The authors found similar and dose-proportionate 
increases in both total and free 25OHD in both groups [25].
 
Sollid et al. studied the relationships 
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 14
between serum total and free 25OHD (both directly and by calculation) in relation to age, sex, 
BMI, season and DBP genotype and their inter-relationship with the weekly administration of 
20,000 units of D3 / placebo for a year in nearly 500 individuals. The authors found that serum 
DBP was not affected by vitamin D supplementation. They demonstrated that age, sex and DBP 
concentration did not affect increment in vitamin D parameters, following supplementation [24].
 
 
If serum free 25OHD increases disproportionately in some ethnic groups following vitamin D 
administration, is this a problem? There is another step beyond 25-hydroxylation in producing the 
biologically active form of vitamin D (1,25(OH)2D), and this step is highly regulated to protect 
against hypercalcaemia. The finding here that PTH did not decrease as expected in White 
Caucasians as both free and total serum 25OHD increased is puzzling. However, PTH did decrease 
in the Asian group; this suggests that the greater increase in free 25OHD in Asians may have 
broader biological significance in terms of calcium metabolism, perhaps reflecting increased 
calcium absorption. Asians had lower baseline total serum 25OHD, and are more likely (as a 
population group) to receive treatment. The concern would be therefore that significantly 
increasing calcium absorption might have unexpected and undesirable consequences in an ethnic 
group already at higher risk for cardiovascular and renal disease. 
 
In the method comparison between the calculated and directly measured serum free 25OHD 
using fixed affinity constant for the DBP genotype, there was a positive but not significant 
systematic bias at baseline. Post supplementation the systematic bias was negative and also non-
significant.  We cannot explain this finding. This may be due to small sample size (figure 3a,b,c,d).  
 
Strengths and Limitations: 
Ours is the first interventional study reported so far, studying the effects of single dose of vitamin 
D3 on serum total 25OHD, DBP and free 25OHD concentration in both Asians and Caucasians. The 
main limitation of our study is the small sample size; hence we had an insufficient statistical 
power to demonstrate the influence of skin types or DBP genotypes on serum 25OHD (total and 
free) with or without vitamin D3 supplementation. We conducted the study exclusively in young 
healthy males; hence our study findings may not be applicable to conditions associated with 
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 15
variation in DBP levels such as gender, pregnancy, liver disease and infections, and may not 
necessarily be applicable across all ages. We also included no functional outcome measures. 
 
Conclusion: 
Our primary aim was to determine the size of the effect of vitamin D supplementation in different 
ethnic groups. In an era of “precision medicine” we should be able to better target vitamin D 
treatment. Rather than adopting a “one size fits all” policy, we should aim to develop measurements 
that accurately reflect vitamin D status across all ethnic groups, and use these to guide treatment for 
relevant functional outcomes. 
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Title: Figure 1. Study design 
 
 
Legend: Figure 1 showing the design of the study 
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Title: Figure(s) 2a,b,c: Change in Total, Free 25OHD and DBP following vitamin D 
dosing. Figure 2d: Change in serum free 25OHD according to mean DBP 
 
 
 
Legend: Figure(s) 2a,2b,2c show the change in total, free 25OHD and VDBP 
following vitamin D dosing. Three-part box plot showing ethnicity in X-axis and 
change in Total 25OHD, VDBP and Free 25OHD in Y-axis. Figure 2d shows the 
change in serum free 25OHD according to mean DBP with shaded circles 
representing Caucasians and clear circles Asians. 
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Title: Figure (s) 3a.b.c.d. Method comparison: Direct  vs. Calculated Free 25OHD-
post supplementation (using fixed affinity constants) 
 
 
 
 
 
 
Legend: 
Figure 3a and 3b show the Bland-Altman plots. Bold line indicates mean 
difference with 95% limits of agreement on either side. Figure 3a demonstrates 
systematic bias between calculated (using fixed affinity constants) and directly 
measured serum free 25OHD at baseline and figure 3b, which is post 
supplementation, does not. Mean serum free 25OHD (directly measured) is 
represented in X axis and the difference between the directly measured and 
calculated free 25OHD is represented on the Y-axis.  Bland-Altman plots the mean 
of X and Y versus the difference between X and Y.  
 
 
Figure(s) 3c and 3d show the Passing and Bablok plots. Bold line indicates the 
calculated regression. With 95% CI either side. The line of no difference is drawn 
at 45 degrees.  
Figure 3c demonstrates no systematic bias but a significant proportional bias at 
baseline. Figure 3d demonstrates neither systematic nor proportional bias post 
supplementation. Serum free 25OHD (directly measured) is represented in X axis 
and the calculated free 25OHD (using fixed affinity constants) represented on the 
Y-axis. Passing and Bablok is a nonparametric regression for method 
comparison.  It fits a straight line between two variables (X and Y) where both are 
measured with error. The intercept of the straight line represents the systematic 
bias between X and Y.  The null hypothesis is zero intercept. If the 95% 
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confidence (CI) crosses zero the systematic bias is not statistically significant. The 
slope measures the amount of proportional bias.  The null hypothesis is a slope of 
one.  If the 95% CI cuts across on the proportional bias is not statistically 
significant. If the two methods are identical, they same they will share a common 
intercept (zero) and a common slope (one).   
 
 
 
 
 
 
Title: Table 1. Baseline demographics table, mean (SD) 
  
Whites 
  
Asians 
  
P value 
Study population 30 30 - 
Age (years) 21.43 (1.54) 22.33 (1.44) 0.66 
Weight (kg) 76.97 (9.16) 70.77 (8.34) 0.34 
Height (cms) 179.95 (5.59) 175.77(5.6) 0.95 
BMI 23.76 (2.51) 22.89 (2.30) 0.61 
Waist : Hip ratio 0.81 (0.05) 0.88 (0.09) 0.30 
Calcium intake (gms/day) 1065.87 (266.88) 1031.23 (382.6) 0.28 
Vitamin D intake (iu/day)* 120 (20, 524) 140 (74,276) 0.29 
Fitzpatrick skin grade 1 - 3 3 - 5 - 
Serum Calcium (mmol/L) 2.31 (0.06) 2.30 (0.05) 0.49 
Serum Phosphate (mmol/L) 1.38 (0.19) 1.36 (0.15) 0.74 
Albumin (g/L) 44.2 (2.2) 43.7 (1.7) 0.32 
 
Legend: Table 1 showing the baseline demographic data and the values are 
expressed in mean (SD) with the p values. 
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Title: Table 2.  Haplotype frequencies by ethnicity and median 25OHD 
concentration at baseline  
Haplotype   Caucasian      Asian Total Haplotype Caucasian Asian 
Median Baseline 25OHD concentration 
(nmol/L) 
Gc1f-1f Obs         0 
Exp         2.5 
5 
2.5 
5 Gc1f-1f - - 
Gc1s-1f Obs         9 
Exp         7.5 
6 
7.5 
15 Gc1s-1f 31.6 20.4 
Gc1s-1s Obs         9 
Exp          8.5 
8 
8.5 
17 Gc1s-1s 40.8 20.4 
Gc2-1f Obs         0 
Exp         1.5 
3 
1.5 
3 Gc2-1f - - 
Gc2-1s Obs        11 
Exp          8.5 
6 
8.5 
17 Gc2-1s 33.2 24 
Gc2-2 Obs         1     
Exp         1.5 
2 
1.5 
3 Gc2-2 22.4 16.4 
Total  30 30 60 Fisher’s exact test, p=0.052  
Legend: Table 2 showing the haplotype frequencies by ethnicity as well the 
difference in median 25OHD concentration (nmol/L) between Caucasians and 
Asians based on their haplotypes. 
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Title: Table 3. Results showing serum total and free 25OHD levels, estimated 
25OHD and PTH levels at baseline and increment post supplementation, mean 
and SD 
  Serum Total  
25OHD 
(nmol/L) 
Serum DBP 
(umol/L) 
Measured Free 
25OHD (pmol/L) 
Calculated 
Free 
 
25OHD(pmol/
L) 
PTH  
(ng/L) 
Baseline Caucasians 34.1 (12.3) 6.6 (3.0) 17.8 (7.5) 13.6 (7.8) 44.6 (14.2) 
  Asians 26.3 (13.7) 4.7 (2.3) 16.7 (10.4) 11.9 (6.8) 69.8 (38.6) 
*p-value 
<0.05 
p value *0.004 *0.001 0.65 0.38 *0.0019 
Increment Caucasians 56.7 (18.3) 0.31 (2.0) 12.2 (13.3) 24.4 (14.5) 2.2 (14.2) 
  Asians 56.2 (12.6) 0.24 (2.0) 18.1 (9.4) 29.4 (20.1) - 4.7 (27.7) 
*p-value 
<0.05 
p value 0.90 0.90 *0.0464 0.29 0.24 
Legend: Table 3 showing serum total and free 25OHD levels [both measured and 
calculated], vitamin D binding protein (DBP) and parathyroid hormone (PTH) 
levels at baseline and their increment post supplementation, expressed in mean 
(SD).  
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